Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,200.75
-0.4%
-29.37
Arrow-Thin-Down
DJI
48,941.90
-1.1%
-557.37
Arrow-Thin-Down
NASDAQ
25,067.80
-0.2%
-46.64
Arrow-Thin-Down
Bitcoin
$80,200.00
+1.6%
+$1,291.24
Arrow-Thin-Down
AAPL
$276.83
-1.2%
-$3.31
Arrow-Thin-Down
AMZN
$271.92
+1.4%
+$3.66
Arrow-Thin-Down
GOOG
$379.64
-0.9%
-$3.58
Arrow-Thin-Down
META
$610.48
+0.3%
+$1.74
Arrow-Thin-Down
MSFT
$413.38
-0.3%
-$1.06
Arrow-Thin-Down
NVDA
$198.52
+0.0%
+$0.07
Arrow-Thin-Down
TSLA
$392.45
+0.4%
+$1.63
Most Active StocksDaily Stock GainersDaily Stock Losers

AbbVie: Pharma's New Kid on the Block

The Abbott Labs spin-off AbbVie is officially on the market.

By Brenton Flynn and Max Macaluso – Jan 2, 2013 at 2:10PM EST

Wondering about that new position in your portfolio? For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to investors on Jan. 2. In the following video, Brenton and Max discuss the key issues that new AbbVie shareholders have to understand.

Read Next

Stocks Mentioned

AbbVie Stock Quote
AbbVie
NYSE: ABBV
$208.16
(+0.76%)+$1.56
Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
NASDAQ: VRTX
$429.89
(+1.41%)+$5.97
Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
NYSE: BMY
$57.36
(-1.48%)-$0.86
Abbott Laboratories Stock Quote
Abbott Laboratories
NYSE: ABT
$87.54
(-2.15%)-$1.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services